All In Biotech

Drug Trial Radar · NCT04176848

CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer

A Phase II Study of CFI-400945 and Durvalumab in Patients With Advanced/Metastatic Triple Negative Breast Cancer (TNBC)

Last checked: Nov 20, 2026Latest source record: Feb 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registry

Status

Active, not recruiting

Enrollment

15

Actual

Start

Aug 10, 2020

Primary completion

Sep 15, 2022

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Canadian Cancer Trials GroupResearch network
Sponsor type
Research network
Collaborators
AstraZeneca; University Health Network, Toronto
First posted
Nov 25, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to find out the effect that CFI-400945 and durvalumab have on breast cancer.

Conditions

  • Breast Cancer

Interventions

  • CFI-400945Drug

    CFI-400945 32 mg: Cycle 1: Days 1-7, then Days 15-21; Cycle 2 on: orally once daily

  • DurvalumabDrug

    Cycle 2 on: Durvalumab 1500mg IV on Day 1 (28 day cycles)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response RateTime frame: 24 months

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • BCCA - Cancer Centre for the Southern Interior

    Kelowna, British Columbia, Canada

  • Juravinski Cancer Centre at Hamilton Health Sciences

    Hamilton, Ontario, Canada

  • Kingston Health Sciences Centre

    Kingston, Ontario, Canada

  • Ottawa Hospital Research Institute

    Ottawa, Ontario, Canada

  • University Health Network

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.